Halothane
NERVOUS SYSTEM
Also known as: anestan, fluothane, ftorotan, narcotan, narcotane, rhodialothan
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Halothane is an ofm drug catalogued in DrugCentral. It was first approved by the FDA in 1958. DrugCentral lists 7 molecular targets, including KCNK2, KCNK3 and KCNK9. Recorded indications include General anesthesia.
- Approval status: ofm (first approved 1958 by the FDA).
- Molecular targets: KCNK2, KCNK3, KCNK9 and KCNK10 (7 listed in DrugCentral).
- Indications: General anesthesia.
- ATC code: N01AB01 (Halogenated hydrocarbons).
- Molecular formula: C2HBrClF3; molecular weight 197.38 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- General anesthesia
Contraindications (5)
- Benign intracranial hypertension
- Conduction disorder of the heart
- Disease of liver
- Low blood pressure
- Malignant hyperthermia
Mechanism & targets
Molecular targets (7)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Potassium channel subfamily K member 2 | KCNK2 | opener | — |
| Potassium channel subfamily K member 3 | KCNK3 | opener | — |
| Potassium channel subfamily K member 9 | KCNK9 | opener | — |
| Potassium channel subfamily K member 10 | KCNK10 | opener | — |
| Potassium channel subfamily K member 18 | KCNK18 | opener | — |
| Glycine receptor (alpha-1/beta) | GLRA1|GLRB | other | — |
| GABA-A receptor; anion channel | GABRP|GABRD|GABRA1|GABRB1|GABRG2|GABRB3|GABRA5|GABRA3|GABRA2|GABRB2|GABRA4|GABRE|GABRA6|GABRG1|GABRG3|GABRQ | positive allosteric modulator | — |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 1958-03-12 | FDA | — | — |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
N01AB01 | NERVOUS SYSTEM › ANESTHETICS › ANESTHETICS, GENERAL › Halogenated hydrocarbons |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Halothane is on its molecule page.
| Molecular formula | C2HBrClF3 |
|---|---|
| Molecular weight | 197.38 g/mol |
| CAS number | — |
| InChIKey | BCQZXOMGPXTTIC-UHFFFAOYSA-N |
| PubChem CID | 3562 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Halothane used for?
DrugCentral lists the following indications for Halothane: General anesthesia.
How does Halothane work?
Its molecular targets in DrugCentral include KCNK2 (opener), KCNK3 (opener), KCNK9 (opener) and KCNK10 (opener).
When was Halothane first approved?
Halothane was first approved by the FDA in 1958.
What is the chemical formula of Halothane?
Halothane has the molecular formula C2HBrClF3 and a molecular weight of 197.38 g/mol.
Browse: all drugs starting with H · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 1356 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL931 — compound record and bioactivity
- PubChem CID 3562 — chemical identifiers
- DrugBank DB01159 — drug record
- FDA UNII UQT9G45D1P — substance identity
- DailyMed: FDA labels for Halothane — current prescribing information (label search)
- UniProt O95069 (KCNK2) — target protein
- UniProt O14649 (KCNK3) — target protein
- UniProt Q9NPC2 (KCNK9) — target protein
- UniProt P57789 (KCNK10) — target protein
- UniProt Q7Z418 (KCNK18) — target protein
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.